Avalo Therapeutics (NASDAQ:AVTX) Price Target Lowered to $30.00 at HC Wainwright

Avalo Therapeutics (NASDAQ:AVTX) had its target price decreased by HC Wainwright from $35.00 to $30.00 in a research note issued to investors on Friday morning, Marketbeat Ratings reports. HC Wainwright currently has a buy rating on the stock.

Other research analysts have also issued research reports about the company. Mizuho increased their target price on Avalo Therapeutics from $39.00 to $45.00 and gave the stock an “outperform” rating in a research report on Thursday, May 14th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Avalo Therapeutics in a research note on Friday, July 24th. BTIG Research reiterated a “buy” rating and issued a $58.00 price objective on shares of Avalo Therapeutics in a report on Tuesday, June 16th. Weiss Ratings lowered Avalo Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 30th. Finally, Piper Sandler restated an “overweight” rating and set a $60.00 target price (up from $48.00) on shares of Avalo Therapeutics in a report on Monday, May 11th. Thirteen investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $45.10.

Avalo Therapeutics Trading Down 2.0%

Shares of AVTX opened at $18.32 on Friday. Avalo Therapeutics has a 1-year low of $8.29 and a 1-year high of $24.27. The firm’s 50-day moving average price is $17.26 and its 200-day moving average price is $16.29. The firm has a market capitalization of $969.13 million, a price-to-earnings ratio of -4.19 and a beta of 0.80.

Avalo Therapeutics (NASDAQ:AVTX) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.25). On average, research analysts forecast that Avalo Therapeutics will post -2.58 EPS for the current fiscal year.

Insiders Place Their Bets

In other Avalo Therapeutics news, insider Mittie Doyle sold 1,450 shares of Avalo Therapeutics stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $18.00, for a total transaction of $26,100.00. Following the completion of the transaction, the insider owned 51,776 shares in the company, valued at approximately $931,968. The trade was a 2.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.46% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Avalo Therapeutics

Several large investors have recently modified their holdings of AVTX. Geode Capital Management LLC grew its position in Avalo Therapeutics by 2.5% during the 2nd quarter. Geode Capital Management LLC now owns 110,460 shares of the company’s stock valued at $552,000 after purchasing an additional 2,648 shares during the last quarter. Nantahala Capital Management LLC grew its holdings in shares of Avalo Therapeutics by 10.6% during the second quarter. Nantahala Capital Management LLC now owns 995,000 shares of the company’s stock valued at $4,965,000 after buying an additional 95,000 shares during the last quarter. Bank of America Corp DE grew its holdings in shares of Avalo Therapeutics by 7,066.8% during the second quarter. Bank of America Corp DE now owns 406,571 shares of the company’s stock valued at $2,029,000 after buying an additional 400,898 shares during the last quarter. Boothbay Fund Management LLC bought a new stake in shares of Avalo Therapeutics during the second quarter valued at approximately $56,000. Finally, Vanguard Group Inc. increased its position in shares of Avalo Therapeutics by 314.9% during the third quarter. Vanguard Group Inc. now owns 692,637 shares of the company’s stock valued at $8,803,000 after acquiring an additional 525,696 shares in the last quarter. Hedge funds and other institutional investors own 87.06% of the company’s stock.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.